1 / 1

SCREENING

SPRINT-2 Design (Naïve Study). 72. Weeks 12. 24. 28. 48. Arm 1: SOC Comparator. PEG 1.5+ RBV 4 wk. Placebo + PEG 1.5   g/kg weekly + RBV 44 wk. Follow-up 24 wk. CONTROL. TW 8 Undetectable. SCREENING. Arm 2: Response Guided Therapy. Follow-up 44 wk.

nevaeh
Download Presentation

SCREENING

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SPRINT-2 Design (Naïve Study) 72 Weeks 12 24 28 48 Arm 1: SOC Comparator PEG 1.5+RBV4 wk Placebo + PEG 1.5 g/kg weekly + RBV 44 wk Follow-up24 wk CONTROL TW 8 Undetectable SCREENING Arm 2: Response Guided Therapy Follow-up44 wk PEG 1.5+RBV4 wk BOC+ PEG 1.5 g/kg + RBV24 wk TW 8 Detectable/TW 24 Undetectable EXPERIMENTAL ARMS Placebo +PEG 1.5 g/kg + RBV 20 wk Follow-up24 wk Arm 3: SOC + Boceprevir PEG 1.5+RBV4 wk BOC + PEG 1.5 g/kg + RBV 44 wk Follow-up24 wk

More Related